illustrate the workforce that studies hyperlinks between cholesterol and the selected diseases (Table 1; Figure 8). Not surprisingly key players with the AD field dominate the global rankings (Figures two, eight). The analysis shows further that OCs are especially sensitive towards the size from the field. In these with all the lowest quantity of articles and also the smallest workforce (PD, ALS, HD), authors produced maximally one offspring indicating that this BACE1 custom synthesis parameter needs a important mass of authors (Figure 8).The TTP values reveal distinct disease-specific origins on the major ten contributors. Notably, in the AD field, these authors entered the field within a single decade starting within the 1990s, whereas, in other fields, these contributors entered following the year 2000 (Figure eight).CONCLUSIONSThe new bibliometric evaluation delivers a detailed view on the improvement and structure of your workforce driving investigation on cholesterol and neurodegenerative diseases and complements content-specific summaries. The analysis revealed that the field started inside the 1950s and remained somewhat small till the 1990s. Except for MS, all fields showed intermittent publications, but a strong development since 2000. The continuous expansion on the workforce for the duration of this period was mainly driven by authors contributing single articles even though their contribution varied among the ailments analyzed. Greater than half on the articles are associated to AD, thus, the family members ties, collaborative connections, and important players of this field dominate the general image. The evaluation has caveats. A key challenge for this along with other bibliometric approaches are ambiguous author names, as distinct authors can share precisely the same name precluding appropriate evaluation (Smalheiser and Torvik, 2009). Evaluation of contributions primarily based on single metrics which include TTP values is context-dependent, unsuited to evaluate junior scientists, and insensitive to ground-breaking contributions from modest teams or from teams that contribute only briefly to a field.AUTHOR CONTRIBUTIONSFWP designed the critique, performed literature queries, wrote and validated the code, analyzed the bibliographic records, ready figures, and wrote the manuscript.FUNDINGThis perform didn’t get certain funding. APC have been paid by the author’s institutional funding from the Centre National de la Recherche Scientifique.ACKNOWLEDGMENTSThe author would prefer to thank Dr. V. Pallottini for beneficial comments on the manuscript.preferential binding of cholesterol as compared with phosphatidylcholine and fatty acids. J. Neurochem. 69, 1746752. doi: 10.1046/j.1471-4159.1997. 69041746.x Bandres-Ciga, S., Diez-Fairen, M., Kim, J. J., and Singleton, A. B. (2020). Genetics of Parkinson’s illness: an introspection of its journey towards precision medicine. Neurobiol. Dis. 137:104782. doi: 10.1016/j.nbd.2020. 104782 Barboza, L. A., and Ghisi, N. C. (2018). Evaluating the present state on the art of Huntington disease analysis: a scientometric analysis. Braz. J. Med. Biol. Res. 51:e6299. doi: 10.1590/1414-431X
Elbeddini et al. Journal of Pharmaceutical Policy and Practice doi.org/10.1186/s40545-021-00379-(2021) 14:COMMENTARYOpen AccessImportance of medication reconciliation in cancer patientsAli Elbeddini1 , Anthony To2, Yasamin Tayefehchamani2 and Cindy Xin WenAbstract Cancer sufferers are a complicated and GSK-3 Purity & Documentation vulnerable population whose medication history is typically substantial. Medication reconciliations within this population are in particular important, due to the fact medication discrepancies c